Grove Bank & Trust’s GoodRx Holdings GDRX Stock Holding History

Grove Bank & Trust’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-104	Closed	-$586	–	628
2023 Q3	$586	Buy	+104	New	+$693	﹤0.01%	725

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LCM

Lakewood Capital Management New York $1.58B AUM 0.92% 1-Year Est. Return

PTC

Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Grove Bank & Trust's GDRX Position: Q4 2023 in Review

Grove Bank & Trust sold out of GoodRx Holdings (GDRX) in Q4 2023, closing a stake of 104 shares — an estimated $586 sold.

Grove Bank & Trust first reported a position in GDRX in Q3 2023 and held it in 1 quarter. The position peaked at $586 in Q3 2023. 143 funds tracked by Wall St. Rank hold GDRX as of Q4 2023.

Grove Bank & Trust reported no remaining GoodRx Holdings position as of Q4 2023 after selling out during the quarter.
Grove Bank & Trust sold 104 GoodRx Holdings shares in Q4 2023, an estimated $586.
Grove Bank & Trust first reported a position in GoodRx Holdings in Q3 2023 and held it in 1 quarter.
Grove Bank & Trust's GoodRx Holdings position peaked at $586 in Q3 2023.
143 funds tracked by Wall St. Rank held GoodRx Holdings as of Q4 2023.

Based on Grove Bank & Trust's 13F filing for Q4 2023, filed 30 Jan 2024.